Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RACIN, A Phase I Study of the Combination of Nivolumab Plus Ipilimumab Associated With Low-dose Radiation, Aspirin, and Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors

Trial Profile

RACIN, A Phase I Study of the Combination of Nivolumab Plus Ipilimumab Associated With Low-dose Radiation, Aspirin, and Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Cyclophosphamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Aspirin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms RACIN
  • Most Recent Events

    • 17 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 12 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top